Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

SRP6158

Sigma-Aldrich

EPO human

recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE)

Sinonimo/i:

EP, EPO-alpha, Epoetin, Erythropoietin-alpha, MGC138142

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

10 μG
696,00 €

696,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.


Scegli un formato

Cambia visualizzazione
10 μG
696,00 €

About This Item

Numero CAS:
Codice UNSPSC:
12352202
NACRES:
NA.32

696,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Origine biologica

human

Ricombinante

expressed in HEK 293 cells

Saggio

≥95% (SDS-PAGE)

Stato

lyophilized

PM

36 kDa (monomer, glycosylated)

Confezionamento

pkg of 10 μg

tecniche

cell culture | mammalian: suitable

N° accesso NCBI

N° accesso UniProt

Condizioni di spedizione

dry ice

Temperatura di conservazione

−70°C

Informazioni sul gene

human ... EPO(2056)

Descrizione generale

The gene EPO (erythropoietin) is mapped to human chromosome 7q22.[1] It is a glycoprotein hormone. EPO is generated in fetal liver and adult kidney. However, it can also be secreted by other organs, such as the heart, brain and lungs.[2] EPO is a member of the EPO/TPO (thrombopoietin) family and is found in the plasma.[3]

Applicazioni

  • EPO (erythropoietin) has been used as a component of the culture medium for cardiac stem cells.[4]
  • In cultured cerebellar granule cells and hippocampal neurons, it has been used to study effect of EPO on glutamate release.[5]
  • It has also been used as a component of endothelial differentiation medium.[6]

Azioni biochim/fisiol

EPO (erythropoietin) regulates red cell production by promoting erythroid differentiation and initiating hemoglobin synthesis.[3] It interacts with EPO receptor and is responsible for the cellular responses. EPO is expressed in many cancers, including breast cancer, renal cancer, gastric cancer, hepatocellular carcinoma and central nervous system tumors. In addition, it is a hypoxia responsive cytokine and a pro-angiogenic factor.[2] This protein also has neuroprotective activity against a variety of potential brain injuries and antiapoptotic functions in several tissue types.[7] It can protect from brain damages due to ischemia and enhances memory as well as cognitive ability in humans suffering from vascular dementia.[7]

Stato fisico

Lyophilized from a PBS solution.

Nota sulla preparazione

Centrifuge the vial prior to opening.

Ricostituzione

Reconstitute in sterile PBS containing 0.1% endotoxin-free, recombinant human serum albumin.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Luis Toro et al.
Kidney international, 93(5), 1131-1141 (2018-02-06)
It is accepted that osteoblasts/osteocytes are the major source for circulating fibroblast growth factor 23 (FGF23). However, erythropoietic cells of bone marrow also express FGF23. The modulation of FGF23 expression in bone marrow and potential contribution to circulating FGF23 has
Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia.
Kawakami M, et al.
The Journal of Biological Chemistry, 276, 39469-39475 (2001)
PlanHab: Hypoxia counteracts the erythropoietin suppression, but seems to exaggerate the plasma volume reduction induced by 3 weeks of bed rest.
Keramidas ME, et al.
Physiological Reports, 4, e12760-e12760 (2016)
Tessa Wilkin et al.
Drug testing and analysis, 9(9), 1456-1471 (2017-03-30)
A horse's success on the racetrack is determined by genetics, training and nutrition, and their translation into physical traits such as speed, endurance and muscle strength. Advances in genetic technologies are slowly explaining the roles of specific genes in equine
Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics.
Fang B, et al.
Blood, 105, 2733-2740 (2005)

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.